Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial

PharmacoEconomics(2022)10.1007/s40273-022-01191-1Source: DataRank Database

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial is a research paper published in PharmacoEconomics (2022). On theSindex it has a DataRank of 0.449. It has been cited 19 times.

N/A

0.449DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (18 grants)Impact (FWCI 2.32)OA: hybridTopics (69)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.449

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (13)

Sabina Sanghera ORCID,Richard M Martin ORCID,Roman Gulati ORCID,Fredrik Wiklund ORCID,Eleanor Walsh ORCID

Live enrichment

PubMed:36201131 PMC:PMC9674711 OpenAlex:https://openalex.org/W4302283317

Cancer Research UK

Grant: C11043/A4286

Cancer Research UK

Grant: C18281/A8145

Cancer Research UK

Grant: C18281/A11326

Cancer Research UK

Grant: C18281/A15064

Cancer Research UK

Grant: C18281/A24432

Cancer Research UK

Grant: C18281/A29019

NCI NIH HHS

Grant: U01 CA253915

Cancer Research UK

Grant: 15064

National Institute for Health Research (NIHR)

Grant: NIHR202411

Cancer Research UK

Grant: 24432

National Institute for Health Research (NIHR)

Grant: NIHR200268

Medical Research Council

Grant: MR/S036709/1

NCI NIH HHS

Grant: R50 CA221836

Medical Research Council

Grant: MR/K025643/1

National Institutes of Health

Grant: 3U01CA253915-06S1

Modeling Precision Interventions for Prostate Cancer Control

National Institutes of Health

Grant: 5R50CA221836-08

Statistical modeling to support population and translational cancer research

National Institute for Health Research (NIHR)

Department of Health

FWCI

2.32

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://link.springer.com/content/pdf/10.1007/s40273-022-01191-1.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40273-022-01191-1.pdf

publisherhttps://link.springer.com/article/10.1007/s40273-022-01191-1/fulltext.html

journalhttps://doi.org/10.1007/s40273-022-01191-1

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36201131

Fields of Study

Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchHealth Systems, Economic Evaluations, Quality of Life03 medical and health sciences0302 clinical medicineHumansMaleMiddle AgedAdultProstate-Specific AntigenCost-Benefit AnalysisProstatic NeoplasmsEarly Detection of CancerState MedicineQuality-Adjusted Life YearsMass ScreeningUnited Kingdom

MeSH Terms

AdultCost-Benefit AnalysisUnited KingdomHumansMaleMass ScreeningMiddle AgedProstatic NeoplasmsState MedicineProstate-Specific AntigenQuality-Adjusted Life YearsEarly Detection of Cancer

Keywords

Quality of Life ResearchHealth economicsProstate cancerHealth administrationPublic healthMedicineDecision analysisQuality-adjusted life yearPharmacoeconomicsCost-effectiveness analysisCost effectivenessOncologyCancerStatisticsIntensive care medicineInternal medicineRisk analysis (engineering)MathematicsNursingMaleAdult330/dk/atira/pure/core/keywords/fohsheb; name=HEHP@Bristolname=ICEPCost-Benefit Analysis/dk/atira/pure/core/keywords/fohsheb610Prostatic NeoplasmsMiddle AgedProstate-Specific Antigenname=HEHP@BristolState MedicineUnited Kingdom/dk/atira/pure/core/keywords/icepHumansMass ScreeningOriginal Research ArticleQuality-Adjusted Life YearsEarly Detection of Cancer/dk/atira/pure/core/keywords/icep; name=ICEP

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score

10.6084/m9.figshare.26667481.v1figshare

Additional file 1 of A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score

10.6084/m9.figshare.26667481figshare